Glucocorticoid Effect

PreclinicalSmall molecule

DDiakonhjemmet Hospital

Glucocorticoid Effect is one of 7 small molecule programs targeting Joint Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Joint DiseaseActive, not recruiting

Joint DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Joint Disease

#DrugCompanyPhaseTrials

Humira

Novartis

Approved

1 2

Firazyr

Takeda

Approved

—3

Nucynta

CCollegium Pharmaceutical, Inc.

Oxycontin

Cyklokapron

Crestor

1 7

Glucocorticoid Effect

DDiakonhjemmet Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Recruiting

Osteoporosis

NCT06395883

Clinical

Trials by Indication[1]

Osteoporosis1 trial

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study

Recruiting·DDiakonhjemmet Hospital··NCT06395883·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Glucocorticoid Effect. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glucocorticoid Effect compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glucocorticoid Effect. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Diakonhjemmet Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDiakonhjemmet Hospital

Glucocorticoid Effect

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Osteoporosis1 trial

References

Drug Info

Quick Facts

Related News